Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial

Infection and Immunity

Volumn 73, Issue 1, 2005, Pages 369-377

  Ekström, Nina ^a   Åhman, Heidi ^a,b   Verho, Jouko ^a   Jokinen, Jukka ^a   Väkeväinen, Merja ^a,c   Kilpi, Terhi ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Wyeth Nordic   (Finland)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPLOID CELL VACCINE; HEPATITIS B VACCINE; HEPTAVALENT PNEUMOCOCAL CONJUGATE VACCINE; IMMUNOGLOBULIN G; MMR II; PNCCRM VACCINE; PNCOMPC VACCINE; PNEUMOCOCCAL CAPSULAR POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; VACCINE;

AGE; ANTIBODY RESPONSE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; ENZYME IMMUNOASSAY; FINLAND; FINOM VACCINE EFFICACY TRIAL; FOLLOW UP; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; INFANT; KINETICS; LICENSING; MAJOR CLINICAL STUDY; OTITIS MEDIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SERODIAGNOSIS; SEROTYPE; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIBODY AFFINITY; HUMANS; IMMUNOGLOBULIN G; INFANT; KINETICS; MENINGOCOCCAL VACCINES; OTITIS MEDIA; PNEUMOCOCCAL VACCINES;

EID: 11144338199     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.1.369-377.2005     Document Type: Article

References (59)

1. Åhman, H., H. Käyhty, P. Tamminen, A. Vuorela, F. Malinoski, and J. Eskola. 1996. Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants. Pediatr. Infect. Dis. J. 15:134-139.
2. Anderson, E. L., D. J. Kennedy, K. M. Geldmacher, J. Donnelly, and P. M. Mendelman. 1996. Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants. J. Pediatr. 128:649-653.
3. Anttila, M., J. Eskola, H. Åhman, and H. Käyhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1614-1621.
4. Anttila, M., J. Eskola, H. Åhman, and H. Käyhty. 1999. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 17:1970-1977.
5. Anttila, M., M. Voutilainen, V. Jäntti, J. Eskola, and H. Käyhty. 1999. Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae. Clin. Exp. Immunol. 118:402-407.
6. Black, S., H. Shinefield, B. Fireman, E. Lewis, P. Ray, J. R. Hansen, L. Elvin, K. M. Ensor, J. Hackell, G. Siber, F. Malinoski, D. Madore, I. Chang, R. Kohberger, W. Watson, R. Austrian, K. Edwards, et al. 2000. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr. Infect. Dis. J. 19:187-195.
7. Black, S. B., H. R. Shinefield, S. Ling, J. Hansen, B. Fireman, D. Spring, J. Noyes, E. Lewis, P. Ray, J. Lee, and J. Hackell. 2002. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr. Infect. Dis. J. 21:810-815.
8. Brown, E. J., S. W. Hosea, and M. M. Frank. 1983. The role of antibody and complement in the reticuloendothelial clearance of pneumococci from the bloodstream. Rev. Infect. Dis. 5:S797-S805.
9. Brown, E. J., S. W. Hosea, C. H. Hammer, C. G. Burch, and M. M. Frank. 1982. A quantitative analysis of the interactions of antipneumococcal antibody and complement in experimental pneumococcal bacteremia. J. Clin. Investig. 69:85-98.
10. Bulkow, L. R., R. B. Wainwright, G. W. Letson, S. J. Chang, and J. I. Ward. 1993. Comparative immunogenicity of four Haemophilia influenzae type b conjugate vaccines in Alaska Native infants. Pediatr. Infect. Dis. J. 12:484-492.
11. Capeding, M. Z., T. Puumalainen, C. P. Gepanayao, H. Käyhty, M. G. Lucero, and H. Nohynek. 2003. Safety and immunogenicity of three doses of an eleven-valent diphtheria toxoid and tetanus protein-conjugated pneumococcal vaccine in Filipino infants. BMC Infect. Dis. 3:17.
12. Chung, G. H., K. H. Kim, R. S. Daum, R. A. Insel, G. R. Siber, S. Sood, R. K. Gupta, C. Marchant, and M. H. Nahm. 1995. The V-region repertoire of Haemophilus influenzae type b polysaccharide antibodies induced by immunization of infants. Infect. Immun. 63:4219-4223.
13. Dagan, R., D. Goldblatt, J. R. Maleckar, M. Yaich, and J. Eskola. 2004. Reduction of antibody response to an 11-valent pneumococcal vaccine co-administered with a vaccine containing acellular pertussis components. Infect. Immun. 72:5383-5391.
14. Dagan, R., R. Melamed, O. Zamir, and O. Leroy. 1997. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr. Infect. Dis. J. 16:1053-1059.
15. Daum, R. S., C. E. Zenko, G. Z. Given, G. A. Ballanco, H. Parikh, and K. Germino. 2001. Magnitude of interference after diphtheria-tetanus toxoids-acellular pertussis/Haemophilus influenzae type b capsular polysaccharide-tetanus vaccination is related to the number of doses administered. J. Infect. Dis. 184:1293-1299.
16. Decker, M. D., K. M. Edwards, R. Bradley, and P. Palmer. 1992. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J. Pediatr. 120:184-189.
17. Eskola, J., T. Kilpi, A. Palmu, J. Jokinen, J. Haapakoski. E. Herva, A. Takala, H. Käyhty, P. Karma, R. Kohberger, G. Siber, and P. H. Mäkelä. 2001. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med. 344:403-409.
18. Eskola, J., J. Ward, R. Dagan, D. Goldblatt, F. Zepp, and C. A. Siegrist. 1999. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet 354:2063-2068.
19. Galil, K., R. Singleton, O. S. Levine, M. A. Fitzgerald, L. Bulkow, M. Getty, B. A. Perkins, and A. Parkinson. 1999. Reemergence of invasive Haemophilus influenzae type b disease in a well-vaccinated population in remote Alaska. J. Infect. Dis. 179:101-106.
20. Goldblatt, D., A. R. Vaz, and E. Miller. 1998. Antibody avidity as a surrogate marker of successful priming by Haemophilus influenzae type b conjugate vaccines following infant immunization. J. Infect. Dis. 177:1112-1115.
21. Granoff, D. M., E. L. Andersen, M. T. Osterholm, S. J. Holmes, J. E. McHugh, R. B. Belshe, F. Medley, and T. V. Murphy. 1992. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J. Pediatr. 121:187-194.
22. Granoff, D. M., S. J. Holmes, M. T. Osterholm, J. E. McHugh, A. H. Lucas, E. L. Anderson, R. B. Belshe, J. L. Jacobs, F. Medley, and T. V. Murphy. 1993. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J. Infect. Dis. 168:663-671.
23. Granoff, D. M., and A. H. Lucas. 1995. Laboratory correlates of protection against Haemophilus influenzae type b disease. Importance of assessment of antibody avidity and immunologic memory. Ann. N. Y. Acad. Sci. 754:278-288.
24. Hostetter, M. K. 1986. Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. J. Infect. Dis. 153:682-693.
25. Huebner, R. E., N. Mbelle, B. Forrest, D. V. Madore, and K. P. Klugman. 2002. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa. Pediatr. Infect. Dis. J. 21:1004-1007.
26. Jaffar, S., A. Leach, P. G. Smith, F. Cutts, and B. Greenwood. 2003. Effects of misclassification of causes of death on the power of a trial to assess the efficacy of a pneumococcal conjugate vaccine in The Gambia. Int. J. Epidemiol. 32:430-436.
27. Jodar, L., J. Butler, G. Carlone, R. Dagan, D. Goldblatt, H. Käyhry, K. Klugman, B. Plikaytis, G. Siber, R. Kohberger, I. Chang, and T. Cherian. 2003. Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants. Vaccine 21:3265-3272.
28. Joseph, H., E. Miller, M. Dawson, N. Andrews, I. Feavers, and R. Borrow. 2001. Meningococcal serogroup A avidity indices as a surrogate marker of priming for the induction of immunologic memory after vaccination with a meningococcal A/C conjugate vaccine in infants in the United Kingdom. J. Infect. Dis. 184:661-662.
29. Käyhty, H., J. Eskola, H. Peltola, L. Saarinen, and P. H. Mäkelä. 1992. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines. J. Infect. Dis. 165(Suppl. 1):S165-S166.
30. Käyhty, H., H. Åhman, K. Eriksson, M. Sörberg, and L. Nilsson. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J., in press.
31. Käyhty, H., H. Åhman, P. R. Rönnberg, R. Tillikainen, and J. Eskola. 1995. Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J. Infect. Dis. 172:1273-1278.
32. Kilpi, T., H. Åhman, J. Jokinen, K. S. Lankinen, A. Palmu, H. Savolainen, M. Grönholm, M. Leinenen, T. Hovi, J. Eskola, H. Käyhty, N. Bohidar, J. C. Sadoff, and P. H. Mäkelä. 2003. Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children. Clin. Infect. Dis. 37:1155-1164.
33. Klugman, K. P., S. A. Madhi, R. E. Huebner, R. Kohberger, N. Mbelle, and N. Pierce. 2003. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. 349:1341-1348.
34. Koskela, M. 1987. Serum antibodies to pneumococcal C polysaccharide in children: response to acute pneumococcal otitis media or to vaccination. Pediatr. Infect. Dis. J. 6:519-526.
35. Leach, A., S. J. Ceesay, W. A. Banya, and B. M. Greenwood. 1996. Pilot trial of a pentavalent pneumococcal polysaccharide/protein conjugate vaccine in Gambian infants. Pediatr. Infect. Dis. J. 15:333-339.
36. Lee, L. H., C. E. Frasch, L. A. Falk, D. L. Klein, and C. D. Deal. 2003. Correlates of immunity for pneumococcal conjugate vaccines. Vaccine 21: 2199-2205.
37. Liu, M. A., A. Friedman, A. I. Oliff, J. Tai, D. Martinez, R. R. Deck, J. T. Shieh, T. D. Jenkins. J. J. Donnelly, and L. A. Hawe. 1992. A vaccine carrier derived from Neisseria meningitidis with mitogenic activity for lymphocytes. Proc. Natl. Acad. Sci. USA 89:4633-4637.
38. Lucero, M. G., T. Puumalainen, J. M. Ugpo, G. Williams, H. Kayhty, and H. Nohynek. 2004. Similar antibody concentrations in Filipino infants at age 9 months, after 1 or 3 doses of an adjuvanted, 11-valent pneumococcal diphtheria/tetanus-conjugated vaccine: a randomized controlled trial. J. Infect. Dis. 189:2077-2084.
39. Manz, R. A., A. Thiel, and A. Radbruch. 1997. Lifetime of plasma cells in the bone marrow. Nature 388:133-134.
40. Mbelle, N., R. E. Huebner, A. D. Wasas, A. Kimura, I. Chang, and K. P. Klugman. 1999. Immunogenicity and impact on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine. J. Infect. Dis. 180:1171-1176.
41. Nahm, M. H., K. H. Kim, P. Andersen, S. V. Hetherington, and M. K. Park. 1995. Functional capacities of clonal antibodies to Haemophilus influenzae type b polysaccharide. Infect. Immun. 63:2989-2994.
42. Nurkka, A., H. Åhman, M. Yaich, J. Eskola, and H. Käyhty. 2001. Serum and salivary anti-capsular antibodies in infants and children vaccinated with octavalent pneumococcal conjugate vaccines, PncD and PncT. Vaccine 20:194-201.
43. Obaro, S. K., Z. Huo, W. A. Banya, D. C. Henderson, M. A. Monteil, A. Leach, and B. M. Greenwood. 1997. A glycoprotein pneumococcal conjugate vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine in Gambian children. Pediatr. Infect. Dis. J. 16:1135-1140.
44. O'Brien, K. L., L. H. Moulton, R. Reid, R. Weatherholtz, J. Oski, L. Brown, G. Kumar, A. Parkinson, D. Hu, J. Hackell, I. Chang, R. Kohberger, G. Siber, and M. Santosham. 2003. Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial. Lancet 362:355-361.
45. O'Brien, K. L., M. C. Steinhoff, K. Edwards, H. Keyserling, M. L. Thoms, and D. Madore. 1996. Immunologic priming of young children by pneumococcal glycoprotein conjugate, but not polysaccharide, vaccines. Pediatr. Infect. Dis. J. 15:425-430.
46. Perez-Melgosa, M., H. D. Ochs, P. S. Linsley, J. D. Laman, M. van Meurs, R. A. Flavell, R. K. Ernst, S. I. Miller, and C. B. Wilson. 2001. Carrier-mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine. Eur. J. Immunol. 31:2373-2381.
47. Puumalainen, T., N. Ekström, R. Zeta-Capeding, J. Ollgren, K. Jousimies, M. Lucero, H. Nohynek, and H. Käyhty. 2003. Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine. J. Infect. Dis. 187:1704-1708.
48. Quataert, S. A., C. S. Kirch, L. J. Wiedl, D. C. Phipps, S. Strohmeyer, C. O. Cimino, J. Skuse, and D. V. Madore. 1995. Assignment of weight-based antibody units to a human antipneumococcal standard reference serum, lot 89-S. Clin. Diagn. Lab. Immunol. 2:590-597.
49. Rennels, M. B., K. M. Edwards, H. L. Keyserling, K. S. Reisinger, D. A. Hogerman, D. V. Madore, I. Chang, P. R. Paradiso, F. J. Malinoski, and A. Kimura. 1998. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants. Pediatrics 101:604-611.
50. Richmond, P., R. Borrow, D. Goldblatt, J. Findlow, S. Martin, R. Morris, K. Cartwright, and E. Miller. 2001. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. J. Infect. Dis. 183:160-163.
51. Santosham, M., M. Wolff, R. Reid, M. Hohenboken, M. Bateman, J. Goepp, M. Cortese, D. Sack, J. Hill, W. Newcomer, et al. 1991. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N. Engl. J. Med. 324:1767-1772.
52. Schlesinger, Y., D. M. Granoff, et al. 1992. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. JAMA 267:1489-1494.
53. Schmitt, H. J., J. Faber, I. Lorenz, B. Schmole-Thoma, and N. Ahlers. 2003. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 21:3653-3662.
54. Shinefield, H. R., S. Black, P. Ray, I. Chang, N. Lewis, B. Fireman, J. Hackell, P. R. Paradiso, G. Siber, R. Kohberger, D. V. Madore, F. J. Malinowski, A. Kimura, C. Le, I. Landaw, J. Aguilar, and J. Hansen. 1999. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers. Pediatr. Infect. Dis. J. 18:757-763.
55. Slifka, M. K., R. Antia, J. K. Whitmire, and R. Ahmed. 1998. Humoral immunity due to long-lived plasma cells. Immunity 8:363-372.
56. Syrjänen, R. K., T. M. Kilpi, T. H. Kaijalainen, E. E. Herva, and A. K. Takala. 2001. Nasopharyngeal carriage of Streptococcus pneumoniae in Finnish children younger than 2 years old. J. Infect. Dis. 184:451-459.
57. Usinger, W. R., and A. H. Lucas. 1999. Avidity as a determinant of the protective efficacy of human antibodies to pneumococcal capsular polysaccharides. Infect. Immun. 67:2366-2370.
58. Wuorimaa, T., R. Dagan, M. Väkeväinen, F. Bailleux, R. Haikala, M. Yaich, J. Eskola, and H. Käyhty. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211-1215.
59. Zangwill, K. M., D. P. Greenberg, C. Y. Chiu, P. Mendelman, V. K. Wong, S. J. Chang, S. Partridge, and J. I. Ward. 2003. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants. Vaccine 21: 1894-1900.